About ContraFect Company
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
Analysts' Top Healthcare Picks: ContraFect (CFRX), Boston Scientific (BSX)
ContraFect Submits Investigational New Drug Application for Bacterial Pneumonia Treatment
ContraFect (CFRX) said Monday it has submitted an investigational new drug application that supports a proposed indication for CF-370 for the treatment of hospital-acquired bacterial pneumonia and ven
ContraFect Reports Submission Of IND Application To FDA For Its Development Candidate CF-370
The IND application supports a proposed indication for its intravenous (IV) antibacterial agent, CF-370, for treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacteri